KYNAPID™ Atrial Fibrillation Injection Approvable

  • By
  • In Industry News
  • August 19, 2008
  • Comments Off on KYNAPID™ Atrial Fibrillation Injection Approvable

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. (“Astellas”) announced they have received an approvable action letter from the FDA for KYNAPID™ (vernakalant hydrochloride) Injection for the treatment of atrial fibrillation (AF), Medical News Today reports. Atrial Fibrillation is a potentially life-threatening condition occurring when electrical signals in the heart malfunction.

Comments are closed.